September 28, 2004 |
The Food and Drug Administration rejected Allergan Inc.'s application for treating psoriasis with tazarotene capsules, the company said Monday. Irvine-based Allergan, best known as the maker of wrinkle-reducing Botox, said regulators asked for a study that showed the drug was not inferior to other treatments for severe psoriasis.
July 13, 2004 |
A Food and Drug Administration advisory panel on Monday rejected Allergan Inc.'s oral psoriasis drug Tazoral because it could cause birth defects when used by pregnant women. Allergan's shares slid nearly 4% after the panel's 9-3 vote and continued to tumble in after-hours trading. Tazoral is aimed at people with moderate to severe psoriasis, but panelists worried that the drug would be prescribed to treat acne, a much more common condition affecting teens and young adults.
May 1, 2004 |
Amgen Inc. won U.S. approval Friday to market its rheumatoid arthritis drug Enbrel as a treatment for the skin disorder psoriasis. A Food and Drug Administration spokeswoman said Enbrel had been approved for chronic moderate to severe psoriasis, an inflammatory condition that causes red, scaly patches of skin and afflicts more than 7 million people in the United States.
January 5, 2004 |
About 5 million Americans suffer from psoriasis, an unsightly, uncomfortable skin condition in which skin cells grow too fast, forming thick, scaly lesions. Topical preparations can relieve only symptoms, and most drugs taken internally have significant and cumulative side effects, including liver damage. Now researchers are taking a new approach: using injectable drugs to keep the immune system from going into overdrive.
December 14, 2003
"A Cheaper and Better Therapy for Psoriasis" (Letters, Nov. 30) told only part of the story. Far from being indifferent to it, the National Psoriasis Foundation has been trying to generate U.S. interest in fumaric acid esters since 1985 and provided advice to its European manufacturer back in 1996. We are thrilled that Biogen Idec has licensed the next generation of this product for the United States, so we can learn more about this drug and finally see whether it can bring relief to Americans with psoriasis who are looking for additional treatment options.
November 30, 2003
Re: "Journal Backs Genentech, Amgen Drugs," Nov. 20: The article in the New England Journal of Medicine is a big boost to these pharmaceutical companies. However, the cost of treatment, $14,000 to $24,000 per year, puts this therapy out of the reach of many people. I have suffered with severe psoriasis for about 30 years. I was treated with every modality known at the time with no success. About eight years ago, I heard of an oral therapy used in Germany with great success. I was able to arrange to take this medication, and in a few months, I was essentially clear of psoriasis.
November 20, 2003 |
A pair of articles in Thursday's New England Journal of Medicine confirm that rival biotechnology drugs from Genentech Inc. and Amgen Inc. are effective treatments for many psoriasis patients. An editorial in the journal signed by dermatologist Dr. Robert C. Kupper of Boston's Brigham and Women's Hospital called the drugs "a boon to patients" but cautioned "there are insufficient data to support claims that one of these agents is superior to the other."
November 10, 2003 |
Researchers have discovered a trio of genes that likely help provide the complex origins of psoriasis, the itchy skin disease triggered when the immune system runs amok. The genes, when defective, increase a patient's susceptibility to the incurable disease that afflicts about 2% of the population, according to a study appearing in the electronic edition of the journal Nature Genetics.
October 28, 2003 |
Genentech Inc.'s Raptiva received Food and Drug Administration approval Monday, raising the stakes in the market for biotech psoriasis drugs. Raptiva, a once-weekly shot, becomes the second biotechnology drug for psoriasis -- a category that some analysts believe could top $1 billion a year by 2006. Biogen Inc.'s intravenous medication Amevive reached the market this year. Genentech's chief rival is likely to be Amgen Inc. of Thousand Oaks.
September 10, 2003 |
A medical advisory panel Tuesday recommended Food and Drug Administration approval of Raptiva, bringing Genentech Inc. closer to entering the coveted market for psoriasis drugs. The expert committee voted 11 to 0 to recommend Raptiva for moderate to severe psoriasis, a chronic skin disease that affects as many as 4 million people in the U.S. The FDA isn't required to follow its panel's advice, but it usually does. The committee acted after the markets closed.